CN111521778A - 一种检测ndm-1耐药蛋白双抗夹心elisa试剂盒及检测方法 - Google Patents
一种检测ndm-1耐药蛋白双抗夹心elisa试剂盒及检测方法 Download PDFInfo
- Publication number
- CN111521778A CN111521778A CN202010542173.1A CN202010542173A CN111521778A CN 111521778 A CN111521778 A CN 111521778A CN 202010542173 A CN202010542173 A CN 202010542173A CN 111521778 A CN111521778 A CN 111521778A
- Authority
- CN
- China
- Prior art keywords
- antibody
- solution
- ndm
- hrp
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000740455 Klebsiella pneumoniae Metallo-beta-lactamase type 2 Proteins 0.000 title claims abstract description 80
- 238000001514 detection method Methods 0.000 title claims abstract description 68
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 31
- 238000003118 sandwich ELISA Methods 0.000 title claims abstract description 31
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 29
- 229940079593 drug Drugs 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 238000001814 protein method Methods 0.000 title description 3
- 238000002965 ELISA Methods 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 19
- 241000894006 Bacteria Species 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 61
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 13
- 239000007853 buffer solution Substances 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 7
- 238000007865 diluting Methods 0.000 claims description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 239000012089 stop solution Substances 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000007974 sodium acetate buffer Substances 0.000 claims description 4
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 3
- 241000872931 Myoporum sandwicense Species 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012224 working solution Substances 0.000 claims description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- YHEPZZFDBQOSSN-UHFFFAOYSA-N bis(1,2,2,6,6-pentamethylpiperidin-4-yl) decanedioate;1-o-methyl 10-o-(1,2,2,6,6-pentamethylpiperidin-4-yl) decanedioate Chemical compound COC(=O)CCCCCCCCC(=O)OC1CC(C)(C)N(C)C(C)(C)C1.C1C(C)(C)N(C)C(C)(C)CC1OC(=O)CCCCCCCCC(=O)OC1CC(C)(C)N(C)C(C)(C)C1 YHEPZZFDBQOSSN-UHFFFAOYSA-N 0.000 claims description 2
- 229940078916 carbamide peroxide Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims 2
- 229960002303 citric acid monohydrate Drugs 0.000 claims 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000589291 Acinetobacter Species 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 108010061238 threonyl-glycine Proteins 0.000 description 5
- SFPRJVVDZNLUTG-OWLDWWDNSA-N Ala-Trp-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFPRJVVDZNLUTG-OWLDWWDNSA-N 0.000 description 4
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 4
- QVTDVTONTRSQMF-WDCWCFNPSA-N Lys-Thr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CCCCN QVTDVTONTRSQMF-WDCWCFNPSA-N 0.000 description 4
- 108010049041 glutamylalanine Proteins 0.000 description 4
- 108010015792 glycyllysine Proteins 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 3
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 3
- NZOAFWHVAFJERA-OALUTQOASA-N Gly-Phe-Trp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O NZOAFWHVAFJERA-OALUTQOASA-N 0.000 description 3
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 3
- VTZYMXGGXOFBMX-DJFWLOJKSA-N His-Ile-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O VTZYMXGGXOFBMX-DJFWLOJKSA-N 0.000 description 3
- DGLAHESNTJWGDO-SRVKXCTJSA-N His-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N DGLAHESNTJWGDO-SRVKXCTJSA-N 0.000 description 3
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 3
- IASQBRJGRVXNJI-YUMQZZPRSA-N Leu-Cys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)NCC(O)=O IASQBRJGRVXNJI-YUMQZZPRSA-N 0.000 description 3
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 3
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 3
- 108010066427 N-valyltryptophan Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- OHKFXGKHSJKKAL-NRPADANISA-N Ser-Glu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OHKFXGKHSJKKAL-NRPADANISA-N 0.000 description 3
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 3
- XPVIVVLLLOFBRH-XIRDDKMYSA-N Ser-Trp-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CO)C(O)=O XPVIVVLLLOFBRH-XIRDDKMYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 3
- XEVHXNLPUBVQEX-DVJZZOLTSA-N Thr-Trp-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N)O XEVHXNLPUBVQEX-DVJZZOLTSA-N 0.000 description 3
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 108010047857 aspartylglycine Proteins 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 241001232615 Acinetobacter baumannii ATCC 19606 = CIP 70.34 = JCM 6841 Species 0.000 description 2
- BIGRHVNFFJTHEB-UBHSHLNASA-N Asn-Trp-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(O)=O BIGRHVNFFJTHEB-UBHSHLNASA-N 0.000 description 2
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 2
- 241000327731 Escherichia coli ATCC 35150 Species 0.000 description 2
- QBEWLBKBGXVVPD-RYUDHWBXSA-N Gln-Phe-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N QBEWLBKBGXVVPD-RYUDHWBXSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 2
- WYKXJGWSJUULSL-AVGNSLFASA-N His-Val-Arg Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O WYKXJGWSJUULSL-AVGNSLFASA-N 0.000 description 2
- AUIYHFRUOOKTGX-UKJIMTQDSA-N Ile-Val-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N AUIYHFRUOOKTGX-UKJIMTQDSA-N 0.000 description 2
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 2
- SZRNDHWMVSFPSP-XKBZYTNZSA-N Ser-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N)O SZRNDHWMVSFPSP-XKBZYTNZSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- JVTHMUDOKPQBOT-NSHDSACASA-N Trp-Gly-Gly Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O)=CNC2=C1 JVTHMUDOKPQBOT-NSHDSACASA-N 0.000 description 2
- XKVXSCHXGJOQND-ZOBUZTSGSA-N Val-Asp-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N XKVXSCHXGJOQND-ZOBUZTSGSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PKIDNTKRVKSLDB-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;hydrate Chemical compound O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PKIDNTKRVKSLDB-UHFFFAOYSA-K 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- SIGTYDNEPYEXGK-ZANVPECISA-N Ala-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 SIGTYDNEPYEXGK-ZANVPECISA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- YFBGNGASPGRWEM-DCAQKATOSA-N Arg-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YFBGNGASPGRWEM-DCAQKATOSA-N 0.000 description 1
- UAOSDDXCTBIPCA-QXEWZRGKSA-N Arg-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UAOSDDXCTBIPCA-QXEWZRGKSA-N 0.000 description 1
- IGFJVXOATGZTHD-UHFFFAOYSA-N Arg-Phe-His Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccccc1)C(=O)NC(Cc2c[nH]cn2)C(=O)O IGFJVXOATGZTHD-UHFFFAOYSA-N 0.000 description 1
- URAUIUGLHBRPMF-NAKRPEOUSA-N Arg-Ser-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O URAUIUGLHBRPMF-NAKRPEOUSA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- ILQCHXURSRRIRY-YUMQZZPRSA-N Asp-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)N ILQCHXURSRRIRY-YUMQZZPRSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- BUIYOWKUSCTBRE-CIUDSAMLSA-N Cys-Arg-Gln Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O BUIYOWKUSCTBRE-CIUDSAMLSA-N 0.000 description 1
- LHLSSZYQFUNWRZ-NAKRPEOUSA-N Cys-Arg-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LHLSSZYQFUNWRZ-NAKRPEOUSA-N 0.000 description 1
- KEBJBKIASQVRJS-WDSKDSINSA-N Cys-Gln-Gly Chemical compound C(CC(=O)N)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N KEBJBKIASQVRJS-WDSKDSINSA-N 0.000 description 1
- LBOLGUYQEPZSKM-YUMQZZPRSA-N Cys-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N LBOLGUYQEPZSKM-YUMQZZPRSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- GNDJOCGXGLNCKY-ACZMJKKPSA-N Gln-Cys-Cys Chemical compound N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O GNDJOCGXGLNCKY-ACZMJKKPSA-N 0.000 description 1
- LVNILKSSFHCSJZ-IHRRRGAJSA-N Gln-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LVNILKSSFHCSJZ-IHRRRGAJSA-N 0.000 description 1
- LVSYIKGMLRHKME-IUCAKERBSA-N Gln-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N LVSYIKGMLRHKME-IUCAKERBSA-N 0.000 description 1
- UESYBOXFJWJVSB-AVGNSLFASA-N Gln-Phe-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O UESYBOXFJWJVSB-AVGNSLFASA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 1
- VUUOMYFPWDYETE-WDSKDSINSA-N Gly-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN VUUOMYFPWDYETE-WDSKDSINSA-N 0.000 description 1
- PDAWDNVHMUKWJR-ZETCQYMHSA-N Gly-Gly-His Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 PDAWDNVHMUKWJR-ZETCQYMHSA-N 0.000 description 1
- TVDHVLGFJSHPAX-UWVGGRQHSA-N Gly-His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 TVDHVLGFJSHPAX-UWVGGRQHSA-N 0.000 description 1
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 1
- ALOBJFDJTMQQPW-ONGXEEELSA-N Gly-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN ALOBJFDJTMQQPW-ONGXEEELSA-N 0.000 description 1
- UTYGDAHJBBDPBA-BYULHYEWSA-N Gly-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN UTYGDAHJBBDPBA-BYULHYEWSA-N 0.000 description 1
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 1
- DHNXGWVNLFPOMQ-KBPBESRZSA-N Gly-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)CN DHNXGWVNLFPOMQ-KBPBESRZSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 1
- SVHKVHBPTOMLTO-DCAQKATOSA-N His-Arg-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SVHKVHBPTOMLTO-DCAQKATOSA-N 0.000 description 1
- CSTNMMIHMYJGFR-IHRRRGAJSA-N His-His-Arg Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CN=CN1 CSTNMMIHMYJGFR-IHRRRGAJSA-N 0.000 description 1
- PZUZIHRPOVVHOT-KBPBESRZSA-N His-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CN=CN1 PZUZIHRPOVVHOT-KBPBESRZSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- XLDYDEDTGMHUCZ-GHCJXIJMSA-N Ile-Asp-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N XLDYDEDTGMHUCZ-GHCJXIJMSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 description 1
- FJWALBCCVIHZBS-QXEWZRGKSA-N Ile-Met-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)O)N FJWALBCCVIHZBS-QXEWZRGKSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- DPWGZWUMUUJQDT-IUCAKERBSA-N Leu-Gln-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O DPWGZWUMUUJQDT-IUCAKERBSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- IFMPDNRWZZEZSL-SRVKXCTJSA-N Leu-Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O IFMPDNRWZZEZSL-SRVKXCTJSA-N 0.000 description 1
- REPBGZHJKYWFMJ-KKUMJFAQSA-N Leu-Lys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N REPBGZHJKYWFMJ-KKUMJFAQSA-N 0.000 description 1
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 1
- FPFOYSCDUWTZBF-IHPCNDPISA-N Leu-Trp-Leu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H]([NH3+])CC(C)C)C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 FPFOYSCDUWTZBF-IHPCNDPISA-N 0.000 description 1
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 1
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 1
- OHXUUQDOBQKSNB-AVGNSLFASA-N Lys-Val-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OHXUUQDOBQKSNB-AVGNSLFASA-N 0.000 description 1
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- AOKZOUGUMLBPSS-PMVMPFDFSA-N Phe-Trp-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O AOKZOUGUMLBPSS-PMVMPFDFSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 1
- QBFONMUYNSNKIX-AVGNSLFASA-N Pro-Arg-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QBFONMUYNSNKIX-AVGNSLFASA-N 0.000 description 1
- WSRWHZRUOCACLJ-UWVGGRQHSA-N Pro-Gly-His Chemical compound C([C@@H](C(=O)O)NC(=O)CNC(=O)[C@H]1NCCC1)C1=CN=CN1 WSRWHZRUOCACLJ-UWVGGRQHSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- HZNFKPJCGZXKIC-DCAQKATOSA-N Ser-His-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CO)N HZNFKPJCGZXKIC-DCAQKATOSA-N 0.000 description 1
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 1
- AOAMKFFPFOPMLX-BVSLBCMMSA-N Trp-Arg-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 AOAMKFFPFOPMLX-BVSLBCMMSA-N 0.000 description 1
- DTPARJBMONKGGC-IHPCNDPISA-N Trp-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N DTPARJBMONKGGC-IHPCNDPISA-N 0.000 description 1
- RPVDDQYNBOVWLR-HOCLYGCPSA-N Trp-Gly-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O RPVDDQYNBOVWLR-HOCLYGCPSA-N 0.000 description 1
- WLBZWXXGSOLJBA-HOCLYGCPSA-N Trp-Gly-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 WLBZWXXGSOLJBA-HOCLYGCPSA-N 0.000 description 1
- NOFFAYIYPAUNRM-HKUYNNGSSA-N Trp-Gly-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)N NOFFAYIYPAUNRM-HKUYNNGSSA-N 0.000 description 1
- XGFGVFMXDXALEV-XIRDDKMYSA-N Trp-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N XGFGVFMXDXALEV-XIRDDKMYSA-N 0.000 description 1
- RWAYYYOZMHMEGD-XIRDDKMYSA-N Trp-Leu-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 RWAYYYOZMHMEGD-XIRDDKMYSA-N 0.000 description 1
- NLWCSMOXNKBRLC-WDSOQIARSA-N Trp-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLWCSMOXNKBRLC-WDSOQIARSA-N 0.000 description 1
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 1
- FBHBVXUBTYVCRU-BZSNNMDCSA-N Tyr-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CN=CN1 FBHBVXUBTYVCRU-BZSNNMDCSA-N 0.000 description 1
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 1
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- IWZYXFRGWKEKBJ-GVXVVHGQSA-N Val-Gln-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N IWZYXFRGWKEKBJ-GVXVVHGQSA-N 0.000 description 1
- DJQIUOKSNRBTSV-CYDGBPFRSA-N Val-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N DJQIUOKSNRBTSV-CYDGBPFRSA-N 0.000 description 1
- RSGHLMMKXJGCMK-JYJNAYRXSA-N Val-Met-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N RSGHLMMKXJGCMK-JYJNAYRXSA-N 0.000 description 1
- JXWGBRRVTRAZQA-ULQDDVLXSA-N Val-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N JXWGBRRVTRAZQA-ULQDDVLXSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 1
- 108010023364 glycyl-histidyl-arginine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108060004734 metallo-beta-lactamase Proteins 0.000 description 1
- 102000020235 metallo-beta-lactamase Human genes 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000009008 sandwich enzyme-linked immunosorbent assay kity Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 108010058119 tryptophyl-glycyl-glycine Proteins 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供一种用于检测细菌中NDM‑1耐药蛋白的双抗夹心ELISA检测试剂盒及其检测方法，包括包被有单克隆抗体8E3的酶标板、检测抗体4G7‑HRP、NDM‑1蛋白标准品。本发明选用8E3作为捕获抗体，4G7‑HRP作为检测抗体研制了NDM‑1双抗夹心ELISA检测试剂盒，并对其进行了方法学系统评估，结果显示试剂盒特异性好，灵敏度高，为NDM‑1阳性耐药菌的快速检测提供了一种技术手段。
Description
技术领域
本发明涉及一种用于检测细菌中NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒及其检测方法，属于免疫学分析技术领域。
背景技术
近年来，由于抗生素在临床大量使用甚至不当使用，在抗生素的选择压力下，临床疾病相关细菌的耐药菌株不断出现，而且出现多重耐药株，由于耐药菌可进行多途径高速率传播，尤其是人畜的交叉感染，严重威胁了人类的生命安全，同时大大增加了临床抗感染的难度。
NDM-1又名“新德里金属-β-内酰胺酶1”，简称为NDM-1。新德里金属β内酰胺酶-1(NDM-1)属于B1亚类金属β内酰胺酶，能水解除氨曲南外的绝大多数β内酰胺类抗菌药物，其基因大多定位在质粒上，易引起水平传播。2010年Kumarasamy等报道了产NDM-1肠杆菌在印度、巴基斯坦以及英国等国家的流行，引起国际性的关注。随后，美国、德国、日本、中国香港等地不断检出携带NDM-1的菌株，多为大肠埃希菌、肺炎克雷伯菌和鲍曼不动杆菌等临床常见的致病菌。据报道，这种病可以通过饮水等途径传染，表现症状为肠道感染，这种新型细菌对几乎所有抗生素都具有抗药性，死亡率很高，不仅在医院中存在，在自然界中也同样存在。
目前现有检测NDM-1的方法主要有纸片扩散法、Etest检测法、微量稀释法、PCR等。其中，纸片扩散法缺乏特异性，仅适合初筛试验，Etest检测法、微量稀释法灵敏度低，而PCR可通过特异性引物对NDM-1阳性细菌进行确证，但对仪器设备的要求较高，且操作复杂，不易在临床应用，而ELISA作为常用的检测微生物的方法，具有快速、灵敏、高通量、特异性好等特点，因此建立一种用于检测NDM-1耐药蛋白的双抗夹心ELISA试剂盒及方法具有重要的应用价值。
发明内容
本发明的目的是提供一种灵敏度高、特异性强、操作简便、检测快速的检测细菌中NDM-1耐药蛋白的双抗夹心酶联免疫试剂盒及检测方法。
为了实现上述目的，本发明采用的技术方案是：
一种用于检测细菌中NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒，包括：包被有单克隆抗体8E3的酶标板、检测抗体4G7-HRP、NDM-1蛋白。
在一个实施方案中，所述检测NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒，包括：
1）重组NDM-1(36-270)蛋白为通过截断NDM-1序列，N端添加HIS标签，克隆至表达载体pET-28a，并转化入大肠杆菌BL21（DE3）宿主菌株中，经IPTG诱导表达，使用Ni-NTA镍柱纯化得到的；
上述重组NDM-1（36-270）蛋白氨基酸序列为序列1；
在一个实施方案中，所述NDM-1单克隆抗体8E3，4G7为采用重组NDM-1（36-270）蛋白免疫小鼠，经融合、克隆、筛选，得到的；
所述单克隆抗体8E3的重链可变区的氨基酸序列为序列2；
所述单克隆抗体8E3的轻链可变区的氨基酸序列为序列3；
所述单克隆抗体4G7的重链可变区的氨基酸序列为序列4；
所述单克隆抗体4G7的轻链可变区的氨基酸序列为序列5。
在一个实施方案中，所述检测抗体4G7-HRP的制备方法包括如下步骤：
（1）称取5 mg HRP溶于1 mL三蒸水中，逐滴缓慢加入0.20 mL新配的0.1 M NaIO4溶液，4℃避光搅拌25 min，活化HRP，颜色由棕色变为绿色；上述溶液装入透析袋中，用1 M，pH4.4的醋酸钠缓冲液中4℃过夜透析，然后10000 r/min，4℃，离心10 min，去除沉淀，得到透析后的HRP；
（2）将单克隆抗体4G7用0.2 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到透析后的抗体；
（3）将透析后的HRP加入0.16 M乙二醇（每mg酶加0.1 mL），4℃避光搅拌1 h，然后加入透析后的抗体；两者混匀后用0.05 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到HRP-抗体混合液；
（4）对0.15 M pH 7.4 PBS透析过夜；搅拌下逐滴加入等体积饱和硫酸氨，4℃避光搅拌3 h；4℃，10000 rpm离心15 min，弃上清；PBS 溶解沉淀，得到经辣根过氧化物酶标记的检测抗体HRP-4G7。
在一个实施方案中，所述检测细菌中NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒，还包括如下步骤：
1）包被有单克隆抗体8E3的酶标板的制备：将单克隆抗体8E3用0.05 M碳酸盐缓冲液（pH 9.6）稀释成浓度为5 μg/mL，每孔100 μL，4℃包被过夜后洗板；然后每孔加入100 μL2% BSA（含0.3%NaN3），37℃，湿度30-40%封闭2 h，然后37℃，湿度30-40%恒温干燥2h；
2）检测抗体稀释液：0.01 M pH 7.4的PBST溶液；
3）检测抗体工作液的制备：检测抗体4G7-HRP按照1:30000比例稀释后备用；
4）样品稀释液的制备：0.01 M pH 7.4的PBS溶液；
5）底物A液的制备：含0.08%过氧化脲、0.025%PEG-2000、3.58%十二水合磷酸氢二钠、0.96%一水合柠檬酸钠水溶液，调pH值至7.4；
6）底物B液的制备：含1.03%一水合柠檬酸钠、0.04% TMB、0.0008%硫代硫酸钠、0.1%光稳定剂292、3 % DMF水溶液，调pH值至5.0。
本发明的第二个目的在于提供一种NDM-1蛋白双抗夹心ELISA检测方法，该方法操作简便，检测快速，特异性强，灵敏度高。
具体的说，一种细菌中NDM-1蛋白双抗夹心ELISA检测法，采用以下步骤：（1）以pH9.6的0.05 M碳酸盐缓冲溶液包被捕获抗体8E3(5 μg/mL)，酶标板中每孔加入100 μL，4℃过夜，使其与酶标板紧密结合；（2）次日，弃去孔内溶液，用洗涤液(PBST)洗板3次，每次3min；每孔加入100 μL2 %BSA（含0.3%NaN3）进行封闭，37℃温育2 h；封闭结束后向酶标板孔内加入细菌裂解液，并同时设置阴性对照孔（0.01 M PB，pH 7.4）和阳性对照孔（NDM-1蛋白，2 ng/mL），100 μL/孔，37℃孵育1 h；（3）弃去孔内溶液，洗板3次后，加入检测抗体4G7-HRP，100 μL/孔，37℃孵育1 h；（4）弃去孔内溶液，洗板3次，最后加入的显色剂TMB溶液（现用现配），每孔100 μL，37℃孵育10 min。在HRP作用下，显色剂发生颜色变化，加入终止液（2M H2SO4）50 μL/孔；（5）测定：用酶标仪检测OD450nm。
在一个实施方案中，所述试剂盒中还包括终止液、封闭液和洗涤液；
具体的所述终止液为2 mol/L硫酸；
所述封闭液为2% BSA（含0.3%NaN3）；
所述洗涤液为含0.1% Tween-20的0.01 M pH7.4 PBST溶液。
所述NDM-1蛋白阳性对照为NDM-1（36-270），浓度为2 ng/mL。
本发明的有益效果是：本发明制备了NDM-1单克隆抗体，并建立了细菌中NDM-1蛋白的双抗夹心ELISA方法，该方法检测NDM-1（36-270）蛋白LOD为0.5 ng/mL，与大肠杆菌、不动杆菌、肺炎克雷伯菌、铜绿假单胞菌无交叉，说明具有良好的特异性。
附图说明
图1 NDM-1蛋白检测结果
图2双抗夹心ELISA法的标准曲线
图3 NDM-1与其他菌属的交叉反应。
具体实施方案
为了使本发明的目的和技术方案更加清楚，下面对本发明的优选实施案例进行详细描述。
1.NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒的组成
本发明的双抗夹心ELISA试剂盒包括包被有单克隆抗体8E3的酶标板、检测抗体4G7-HRP、NDM-1蛋白标准品、包被缓冲液、检测抗体稀释液、检测抗体工作液、样本稀释液、底物A液、底物B液、显色液、终止液、封闭液、洗涤液。
2. NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒的制备
1）制备NDM-1蛋白
A、NDM-1基因的合成
从Genebank中获取NDM-1基因的氨基酸序列（Accession: AFI72857.1），依据大肠杆菌的密码子偏好性进行NDM-1基因的碱基序列的密码子优化，并委托南京金斯瑞生物科技有限公司合成了密码子优化后的基因序列。
B、载体的构建
通过截断目的片段（29-270），用GST标签表达，克隆至表达载体pGS-21a，GST-tag+ TEVcleavage site + NDM-1(29-270)；
C、 NDM-1重组蛋白的表达与纯化
构建完成的重组质粒转入感受态细胞转化入大肠杆菌BL21(DE3)宿主菌株中，挑取单菌落接种至含有50 μg/mL卡那霉素的LB培养基中，37℃，200 rpm培养至OD600达到0.6~0.8时，加入终浓度为0.5 mM的IPTG，25℃条件下进行诱导表达。
4℃条件下，3200 g离心15 min收集菌体；然后使用20 mM Tris-HCl（含150 mMNaCl）重悬菌体，3000 W，10 s/10s，15 min超声裂解菌体。采用Ni-NTA镍柱纯化系统纯化表达的NDM-1重组蛋白，得到NDM-1(36-270)蛋白，用作免疫原制备鼠单克隆抗体。
2）NDM-1单克隆抗体的制备
A、免疫实验动物
取步骤2制备的免疫原溶液，将免疫原用无菌生理盐水稀释至1 mg/mL，首次免疫加入等量的弗氏完全佐剂，完全乳化后，采用颈背部皮下、多点注射的方式免疫8只小鼠，免疫剂量为100 μg/只。共免疫6次，每次免疫间隔时间均为2周，具体免疫程序见表1。
表1. 单克隆抗体（小鼠）的免疫程序
B、抗血清的筛选
四免一周后，对小鼠眼眶采血，室温放置2 h，4000 rpm离心10 min后取血清检测；抗血清筛选先采用间接ELISA方阵滴定法确定包被原、抗体的最佳工作浓度，再采用间接竞争ELISA方法检测抗体的特异性和灵敏度。
C、杂交瘤细胞株的融合与筛选
按照常规方法进行，取免疫小鼠的脾细胞与处于对数生长期的小鼠骨髓瘤细胞(SP2/0)混合，然后用50％PEG进行免疫融合，用HAT培养基悬浮均匀，再加入适量的饲养细胞，培养于96孔培养板，于37℃，5％CO2培养箱中培养，5天后用HAT培养基半换液，9天时候进行全换液。
细胞融合后，待细胞长到培养孔面积的1/4时，吸出杂交瘤细胞上清液，并采用NDM-1（36-270）蛋白包被酶标板及间接ELISA方法筛选阳性、效价高的培养孔，得到的阳性孔用中国农业大学提供的NDM-1阳性大肠杆菌、不动杆菌、肺炎克雷伯菌、铜绿假单胞菌裂解液包被的酶标板检测细胞的交叉反应，挑选所有NDM-1阳性菌株均有反应的强阳性孔进行性亚克隆。其中NDM-1阳性菌的鉴定方法参照：Nordmann,Patrice et al. How todetect NDM-1 producers. J Clin Microbiol. 2011, 49 (2): 718-21.
将数次亚克隆后的杂交瘤细胞扩大培养，收集上清液用间接ELISA测定效价，冻存；并取8-10周龄Balb/c小鼠腹腔注射0.3 mL/只含1.3x106个细胞的细胞悬液。6天后观察小鼠，当小鼠腹部膨大时，抽取腹水，每隔2天观察小鼠，及时抽取腹水；将抽取的腹水10000 r/min离心5 min，收集上清，分装保存于-20℃冰箱。
D、腹水中抗体的纯化
将5 mL腹水在10000 r/min、4℃条件下离心5 min，收集上清液，然后加入20 mL倍体的0.06 mM醋酸钠缓冲液（pH 4.0）进行稀释，再使用0.2 M NaOH调节pH至4.5左右；加入1000μL正辛酸缓慢加入正辛酸并搅拌30 min，4℃静置1 h；将上述液体在6000 r/min、4℃条件下离心30 min，收集上清并过滤；加入2.6 mL的PBS缓冲液进行稀释（加入的量应为上述滤液的10%）；加入等体积的饱和硫酸铵，并搅拌30 min，4℃静置1 h；弃上清，加入适量PBS缓冲液重悬后装入透析袋，置于0.02 mM PBS缓冲液中与4℃透析24-48 h并适时换液，收集透析袋内液体，-20℃保存，得到单克隆抗体。
测序结果，单克隆抗体8E3的重链可变区的氨基酸序列为序列2；单克隆抗体8E3的轻链可变区的氨基酸序列为序列3；单克隆抗体4G7的重链可变区的氨基酸序列为序列4；单克隆抗体4G7的轻链可变区的氨基酸序列为序列5。
E、经辣根过氧化物酶标记的NDM-1检测抗体的制备方法：
（1）称取5 mg HRP（辣根过氧化物酶，购自Sigma）溶于1 mL三蒸水中，逐滴缓慢加入0.20 mL新配的0.1 M NaIO4溶液，4℃避光搅拌25 min，活化HRP，颜色由棕色变为绿色。上述溶液装入透析袋中，用1 M，pH为4.4的醋酸钠缓冲液透析，4℃过夜。10000 r/min，4℃，10min，离心去除沉淀。得到透析后的HRP。
（2）将4G7检测抗体用0.2 M，pH为9.5的碳酸缓冲液4℃透析过夜。观察是否有沉淀，并分析沉淀性状，10000 r/min，4℃，10 min，离心去除沉淀，得到透析后的抗体。
（3）将透析后的HRP加入0.16 M乙二醇（每mg酶加0.1 mL），4℃避光搅拌1 h，然后加入透析后的抗体；两者混匀后用0.05 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到HRP-抗体混合液；
（4）将上述溶液装入透析袋中，对0.15 M pH 7.4 PBS透析过夜。搅拌下逐滴加入等体积饱和硫酸氨，4℃避光搅拌3 h。4℃，10000 rpm离心15 min，弃上清。PBS溶解沉淀，得到经辣根过氧化物酶标记的4G7-HRP检测抗体。
F、包被有8E3单克隆抗体的酶标板的制备
将8E3单克隆抗体用碳酸盐缓冲液稀释成浓度为5 μg/mL的抗体包被液，每孔100 μL，4℃包被过夜后洗板；然后每孔加入100 μL封闭液，37℃、湿度30-40%封闭2 h，37℃、湿度30-40%恒温干燥2 h。
3.NDM-1双抗夹心Elisa检测方法建立
A、双抗体夹心ELISA检测法测定步骤
（1）用0.05 M，pH 9.5碳酸盐缓冲液包被捕获抗体8E3(2 ng/mL)，在96孔酶标板中每孔加入100 μL，4℃包被过夜，使其与酶标板紧密结合；
（2）次日，弃去孔内溶液，洗板3次，每次3 min；每孔再加100 μL封闭液，37℃温育2 h；封闭结束后，弃去孔内溶液，洗板3次，在酶标板孔内加入待测蛋白提取物溶液(以待测样品与PBS缓冲液的体积比为稀释倍数)和NDM-1蛋白(每孔4 ng/mL)，100 μL/孔，37℃孵育1 h；
（3）接着加入检测抗体4G7-HRP，100 μL/孔，37℃孵育1 h；
（4）最后在形成的复合物中加入临时配制的显色剂TMB溶液，每孔100 μL，37℃孵育10～30 min。在HRP作用下，显色剂发生颜色变化，加入终止液50 μL/孔；
（5）测定：用酶标仪检测OD450nm。
B、方法的建立
（1）NDM-1蛋白的线性范围
将NDM-1蛋白标准品作系列稀释至0.5~16 ng/mL，用上述建立的双抗体夹心ELISA方法进行检测，进行3次重复，以NDM-1蛋白标准品质量浓度(ng/mL)为横坐标，A450 nm值为纵坐标，用origin8.0 (OriginLab Corp, Northampton, MA, USA) 软件中的四参数拟合标准曲线，确定线性范围与检测限LOD（LOD是空白的平均吸收值加3倍的空白吸收值的标准偏差对应的抗原浓度）。
（2） 特异性验证
以最佳配对的抗体以及最佳浓度来进行双抗体夹心ELISA检测特异性，分别用NDM-1阳性的大肠杆菌，不动杆菌，肺炎克雷伯氏菌，铜绿假单胞菌，以及大肠杆菌ATCC 25922，大肠杆菌ATCC35150，鲍曼不动杆菌ATCC 19606，肺炎克雷伯氏菌ATCC 10031，铜绿假单胞菌ATCC 9027进行特异性检测。
4.结果
1）重组蛋白诱导表达鉴定
NDM-1蛋白分子表达量为27.1KDa，与预期融合蛋白分子量大小一致，可以满足免疫动物和抗体筛选与鉴定的要求，见图1。
2）ELISA检测方法建立
（1）标准曲线：通过测试数据拟合曲线表明（图2），本方法对NDM-1，检出限为0.5 ng/mL，R2=0.9963，方程为Y=2.387+(0.222-2.387)/(1+(x/1.096)^1.723)。
（2）特异性的检测
以最佳配对的抗体以及最佳浓度来进行双抗体夹心ELISA检测特异性．其分别与带有NDM-1的大肠杆菌，不动杆菌，肺炎克雷伯菌，铜绿假单胞菌进行特异性检测（图3）。结果表明，与NDM-1阳性的的大肠杆菌，不动杆菌，肺炎克雷伯菌，铜绿假单胞菌进行特异性检测均有交叉反应，与标准菌株大肠杆菌ATCC 25922，大肠杆菌ATCC 35150，鲍曼不动杆菌ATCC19606，肺炎克雷伯氏菌ATCC 10031，铜绿假单胞菌ATCC 9027无交叉反应，说明特异性良好。
序列表
<110> 北京明日达科技发展有限责任公司
<120> 一种检测NDM-1耐药蛋白双抗夹心ELISA试剂盒及检测方法
<141> 2020-06-15
<150> 202010180297X
<151> 2020-03-16
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 705
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
ggtcaacaga tggaaaccgg cgatcaacgc tttggcgacc tggtcttccg tcaactggct 60
ccgaacgtct ggcagcatac ctcatatctg gatatgccgg gctttggtgc agtggcttcg 120
aacggcctga tcgttcgtga tggcggtcgt gtcctggtgg ttgacaccgc ctggacggat 180
gaccagaccg cccaaattct gaactggatc aaacaggaaa ttaatctgcc ggtggccctg 240
gcggttgtga cccatgcaca ccaagataaa atgggcggta tggatgcact gcatgccgca 300
ggcattgcta cgtatgcaaa cgctctgagc aatcagctgg ccccgcaaga aggtatggtt 360
gcagctcagc actctctgac ctttgccgca aatggttggg tggaaccggc caccgccccg 420
aattttggtc cgctgaaagt tttctacccg ggcccgggtc acaccagcga taacatcacg 480
gtcggcattg atggtaccga catcgcgttc ggcggttgcc tgattaaaga tagcaaagcg 540
aaatctctgg gcaatctggg tgatgccgac acggaacatt acgcagctag cgcacgtgct 600
tttggtgcgg ccttcccgaa agcgagtatg atcgttatgt cccactctgc cccggactct 660
cgtgccgcta tcacccacac cgctcgtatg gctgacaaac tgcgt 705
<210> 2
<211> 114
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Gly Ala Thr Ala Gly Val Trp Gly Leu Thr Gly Lys Thr Trp Gly Phe
1 5 10 15
Ser Glu Val Val Leu Gln Gly Phe Trp Leu His Leu Tyr His Leu Ala
20 25 30
Val Leu Val Gly Lys Thr Glu Ala Trp Thr Gly Ser Gly Val Asp Trp
35 40 45
Gly His Leu Ser Trp Lys Trp Arg Phe His Val Arg Ser Lys Val Gln
50 55 60
Arg Ile Gly His Ile Asp Gln Cys Cys Arg Val Gln His Ser His Met
65 70 75 80
Ser Thr Gln Gln Phe Gly Ile Leu Gly Leu Cys Gly Leu Leu Leu Cys
85 90 95
Asn Trp Asp Gly Val Tyr Leu Leu Gly His Arg Asp Pro Gly His Arg
100 105 110
Leu Leu
<210> 3
<211> 114
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Asp Ile Val Ala Gly Val Trp Gly Lys Thr Gly Lys Thr Trp Gly Phe
1 5 10 15
Ser Glu Val Val Leu Gln Gly Phe Trp Leu His Leu Tyr Lys Leu Leu
20 25 30
Val Ala Val Gly Lys Thr Glu Ala Trp Thr Gly Ser Gly Val Asp Trp
35 40 45
Gly His Val Ser Trp Lys Val Met Phe His Val Arg Ser Lys Val Gln
50 55 60
Gly Gln Cys His Ile Asp Cys Arg Ile Ile Val Gln His Ser His Met
65 70 75 80
Ser Thr Gln Gln Phe Gly Ile Met Gly Leu Cys Gly Leu Leu Leu Tyr
85 90 95
Asn Trp Asp Gly Val Tyr Leu Leu Gly Pro Arg His Asp His Gly Arg
100 105 110
Leu Leu
<210> 4
<211> 115
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Val Ile Val Ala Gly Trp Gly Thr Thr Gly Lys Thr Trp Gly Phe Ser
1 5 10 15
Glu Val Val Leu Gln Gly Phe Trp Leu Leu Lys His Leu Lys Leu Val
20 25 30
Ala Val Gly Lys Thr Glu Ala Trp Thr Gly Gly His Val Asp Gly Ser
35 40 45
Trp Leu Ser Trp Lys Val Gly Phe His Val Arg Ser Lys Val Gln Cys
50 55 60
Gln Gly His Ile Asp Cys Arg Ser Ile Val Gln His Ser His Met Gln
65 70 75 80
Gln Phe Ser Thr Gly Leu Gly Ile Asp Cys Gly Leu Trp Leu Asn Leu
85 90 95
Tyr Asp Gly Val Tyr Leu Leu Gly Pro Arg Asp His Gly His Arg Leu
100 105 110
Leu Leu Cys
115
<210> 5
<211> 112
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Asp Ile Val Ala Gly Val Trp Gly Gly Thr Gly Lys Thr Trp Gly Phe
1 5 10 15
Ser Glu Val Val Leu Gln Gly Phe Trp Leu Gly Leu His Tyr Gly Leu
20 25 30
Val Ala Val Gly Lys Thr Glu Ala Trp Thr Gly Val His Pro Ser Asp
35 40 45
Trp Gly Gly Ser Trp Lys Trp Cys Phe Lys Val Arg Ser Lys Val Gln
50 55 60
Cys Gln Gly His Ile Asp Cys Arg Gln Ile Val Gln His Ser His Met
65 70 75 80
Gln Gln Phe Gly Ser Thr Ile Gly Gly Leu Cys Gly Leu Trp Leu Gly
85 90 95
Leu Tyr Asp Gly Val Tyr Leu Leu Gly Pro Arg Asp His His Arg Leu
100 105 110
Claims (10)
1.一种用于检测细菌中NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒，包括：包被有单克隆抗体8E3的酶标板、检测抗体4G7-HRP、NDM-1蛋白标准品。
2.根据权利要求1所述的检测NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于：
所述单克隆抗体8E3和检测抗体4G7为采用重组NDM-1蛋白免疫小鼠，经融合、克隆、筛选，得到的。
3.根据权利要求1或2所述的检测NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于：
所述单克隆抗体8E3的重链可变区的氨基酸序列为序列2；
所述单克隆抗体8E3的轻链可变区的氨基酸序列为序列3；
所述单克隆抗体4G7的重链可变区的氨基酸序列为序列4；
所述单克隆抗体4G7的轻链可变区的氨基酸序列为序列5。
4.根据权利要求2所述的检测NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于：
重组NDM-1(36-270)蛋白为通过截断NDM-1序列目的片段，N端添加His-tag标签，克隆至表达载体pET-28a，并转化入大肠杆菌BL21（DE3）宿主菌株中，IPTG诱导表达，使用Ni-NTA镍柱纯化得到的。
5.根据权利要求4所述的检测NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于，重组NDM-1(36-270)蛋白氨基酸序列为序列1。
6.根据权利要求1所述的检测NDM-1耐药蛋白的双抗夹心ELISA检测试剂盒，其特征在于，所述检测抗体4G7-HRP的制备方法如下：
（1）称取5 mg HRP溶于1 mL三蒸水中，逐滴缓慢加入0.20 mL新配的0.1 M NaIO4溶液，4℃避光搅拌25 min，活化HRP，颜色由棕色变为绿色；上述溶液装入透析袋中，用1 M，pH为4.4的醋酸钠缓冲液中4℃过夜透析，然后10000 r/min，4℃，离心10 min，去除沉淀；得到透析后的HRP；
（2）将单克隆抗体4G7用0.2 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到透析后的抗体；
（3）将透析后的HRP加入0.16 M乙二醇（每mg酶加 0.1 mL），4℃避光搅拌1 h，然后加入透析后的抗体；两者混匀后用0.05 M，pH为9.5的碳酸缓冲液4℃透析过夜，得到HRP-抗体混合液；
（4）对0.15 M pH7.4 PBS透析过夜；搅拌下逐滴加入等体积饱和硫酸氨，4℃避光搅拌3h；4℃，10000 rpm离心15 min，弃上清；PBS溶解沉淀，得到经辣根过氧化物酶标记的检测抗体4G7-HRP，使用酶标记物稀释液1:30000倍稀释后备用。
7.一种制备权利要求1-6中任一所述的试剂盒的方法，包括如下步骤：
1）包被有单克隆抗体8E3的酶标板的制备：将单克隆抗体8E3用碳酸盐缓冲液稀释成浓度为5 μg/mL的抗体包被液，每孔100 μL，4℃包被过夜后洗板；然后每孔加入100 μL封闭液，37℃、湿度30-40%封闭2 h，37℃、湿度30-40%恒温干燥2 h；
2）检测抗体稀释液：0.01 M pH7.4的PBST溶液；
3）检测抗体工作液的制备：检测抗体4G7-HRP按照1:30000比例稀释后备用；
4）样品稀释液的制备：0.01 M pH7.4的PBS溶液；
5）底物A液的制备：含0.08%过氧化脲、0.025%PEG-2000、3.58%十二水合磷酸氢二钠、0.96%一水合柠檬酸水溶液，调pH值至7.4；
6）底物B液的制备：含1.03%一水合柠檬酸、0.04% TMB、0.0008%硫代硫酸钠、0.1%光稳定剂292、3% DMF水溶液，调pH值至5.0。
8.一种用于检测NDM-1耐药蛋白的双抗夹心ELISA检测法，其特征在于：
（1）向包被有单克隆抗体8E3的酶标板中加入细菌菌体裂解液和NDM-1（36-270）蛋白稀释液，100 μL/孔，37℃孵育1 h；
（2）用PBST洗涤三次，每次3 min，200 μL/孔，然后甩干反应板；
（3）接着加入检测抗体4G7-HRP，100 μL/孔，37℃孵育1 h；
（4）用PBST洗涤三次，每次3 min，200 μL/孔，然后甩干反应板；
（5）最后在形成的复合物中加入临时配制的显色剂TMB溶液，每孔100 μL，37℃孵育10～30 min，在HRP作用下，显色剂发生颜色变化，加入终止液50 μL/孔；
（6）测定：用酶标仪检测OD450nm。
9.根据权利要求1所述的试剂盒或权利要求8所述的方法，其特征在于：所述试剂盒中还包括终止液、封闭液和洗涤液；
具体的所述终止液为3 mol/L硫酸铵；
所述封闭液为2% BSA；
所述洗涤液为含0.1% Tween-20的0.01 M pH 7.4 PBST溶液。
10.根据权利要求8所述的方法，其特征在于，所述细菌菌体裂解液的制备方法为：
4℃条件下，3500 g离心15 min收集菌体，然后使用20 mM Tris-HCl（含150 mM NaCl）重悬菌体，通过超声裂解菌体，超声条件为3000 W，10 s/10s，15 min。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010180297 | 2020-03-16 | ||
| CN202010180297X | 2020-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111521778A true CN111521778A (zh) | 2020-08-11 |
Family
ID=71909950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010542173.1A Pending CN111521778A (zh) | 2020-03-16 | 2020-06-15 | 一种检测ndm-1耐药蛋白双抗夹心elisa试剂盒及检测方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111521778A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113150137A (zh) * | 2021-02-01 | 2021-07-23 | 深圳市龙华区疾病预防控制中心 | 一种ndm-1单克隆抗体的制备方法及其应用 |
| CN114755420A (zh) * | 2022-05-30 | 2022-07-15 | 广东聚诚生物技术有限公司 | 碳青霉烯酶联合检测试剂盒 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101303349A (zh) * | 2008-06-02 | 2008-11-12 | 中国农业科学院兰州兽医研究所 | 一种猪囊尾蚴病间接elisa检测试剂盒及其制备方法 |
| CN102965377A (zh) * | 2012-08-30 | 2013-03-13 | 广东医学院 | 一种新德里金属β内酰胺酶1核酸适体及其筛选方法和应用 |
| CN104215775A (zh) * | 2014-09-04 | 2014-12-17 | 北京纳百景弈生物科技有限公司 | 青霉素结合蛋白PBP6的β-内酰胺类抗生素受体法检测试剂盒制备方法及检测方法 |
| CN106370855A (zh) * | 2016-09-28 | 2017-02-01 | 吉林大学 | 基于BSaBA信号放大系统的绵羊过氧化物氧还酶6双抗夹心ELISA试剂盒 |
| US20170097356A1 (en) * | 2004-07-30 | 2017-04-06 | Promega Corporation | Covalent tethering of functional groups to proteins and substrates therefor |
-
2020
- 2020-06-15 CN CN202010542173.1A patent/CN111521778A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170097356A1 (en) * | 2004-07-30 | 2017-04-06 | Promega Corporation | Covalent tethering of functional groups to proteins and substrates therefor |
| CN101303349A (zh) * | 2008-06-02 | 2008-11-12 | 中国农业科学院兰州兽医研究所 | 一种猪囊尾蚴病间接elisa检测试剂盒及其制备方法 |
| CN102965377A (zh) * | 2012-08-30 | 2013-03-13 | 广东医学院 | 一种新德里金属β内酰胺酶1核酸适体及其筛选方法和应用 |
| CN104215775A (zh) * | 2014-09-04 | 2014-12-17 | 北京纳百景弈生物科技有限公司 | 青霉素结合蛋白PBP6的β-内酰胺类抗生素受体法检测试剂盒制备方法及检测方法 |
| CN106370855A (zh) * | 2016-09-28 | 2017-02-01 | 吉林大学 | 基于BSaBA信号放大系统的绵羊过氧化物氧还酶6双抗夹心ELISA试剂盒 |
Non-Patent Citations (2)
| Title |
|---|
| CUSABIO: "New Delhi metallo-beta-lactamase-1 (NDM-1) ELISA Kit", CUSABIO * |
| XIAOHUA HE 等: "Development of novel antibodies for detection of mobile colistinresistant bacteria contaminated in meats", SCIENTIFIC REPORTS * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113150137A (zh) * | 2021-02-01 | 2021-07-23 | 深圳市龙华区疾病预防控制中心 | 一种ndm-1单克隆抗体的制备方法及其应用 |
| CN113150137B (zh) * | 2021-02-01 | 2022-02-15 | 深圳市龙华区疾病预防控制中心 | 一种ndm-1单克隆抗体的制备方法及其应用 |
| CN114755420A (zh) * | 2022-05-30 | 2022-07-15 | 广东聚诚生物技术有限公司 | 碳青霉烯酶联合检测试剂盒 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111487417B (zh) | Mcr-1耐药蛋白双抗夹心elisa检测试剂盒及检测方法 | |
| CN113150137B (zh) | 一种ndm-1单克隆抗体的制备方法及其应用 | |
| CN111521778A (zh) | 一种检测ndm-1耐药蛋白双抗夹心elisa试剂盒及检测方法 | |
| CN113527476B (zh) | 抗h5亚型禽流感病毒新纳米抗体及其应用 | |
| Zhang et al. | Identification of linear B cell epitope on gB, gC, and gE proteins of porcine pseudorabies virus using monoclonal antibodies | |
| CN111487418B (zh) | Ndm-1耐药蛋白双抗夹心elisa检测试剂盒及检测方法 | |
| CN106699884B (zh) | 抗人c-反应蛋白抗体及其应用 | |
| CN111793130B (zh) | 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用 | |
| CN113150138B (zh) | 一种kpc-2单克隆抗体及其制备方法和应用 | |
| CN108034637B (zh) | Gr79-epsps的单克隆抗体试纸条及其应用 | |
| CN106596976B (zh) | .人c-反应蛋白胶体金定量检测卡 | |
| CN116925218A (zh) | 小热休克蛋白hspb1的抗体、抗体组合物、杂交瘤细胞株及其应用 | |
| CN111487416B (zh) | optrA耐药蛋白双抗夹心ELISA检测试剂盒及检测方法 | |
| CN106749659B (zh) | 一种抗人crp抗体及其应用 | |
| CN112898422B (zh) | 一种烟草环斑病毒单克隆抗体及其制备方法和应用 | |
| CN110894236B (zh) | 一种抗曲霉菌半乳甘露聚糖的单克隆抗体及其应用 | |
| CN114280306A (zh) | 牛筋草epsps蛋白elisa检测试剂盒及检测方法 | |
| CN108047330B (zh) | Cry2Ah1蛋白的单克隆抗体 | |
| CN108004214B (zh) | Homer2单克隆抗体及其应用 | |
| CN110894235A (zh) | 一种抗隐球菌夹膜多糖的兔源单克隆抗体及其应用 | |
| CN110343715A (zh) | pET-28a-SUMO-凝血因子II蛋白抗原及其多克隆抗体的制备方法 | |
| CN110540598B (zh) | 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法 | |
| CN110540599A (zh) | 基于肺炎克雷伯菌表面蛋白抗体的肺炎克雷伯菌Elisa检测试剂盒及制备方法 | |
| US9513287B1 (en) | High affinity monoclonal antibodies for detection of shiga toxin 2 | |
| CN116925219B (zh) | 小热休克蛋白hspb1的抗体、杂交瘤细胞株及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200811 |
|
| WD01 | Invention patent application deemed withdrawn after publication |